[1]王富权,柴 斌,周国锋.中性粒细胞与淋巴细胞比值对TACE联合阿帕替尼治疗进展期肝癌疗效的预测价值[J].介入放射学杂志,2021,30(03):244-248.
　WANG Fuquan,CHAI Bin,ZHOU Guofeng..The value of neutrophil-to-lymphocyte ratio in predicting the curative effect of TACE combined with apatinib for advanced hepatocellular carcinoma[J].journal interventional radiology,2021,30(03):244-248.
点击复制

中性粒细胞与淋巴细胞比值对TACE联合阿帕替尼治疗进展期肝癌疗效的预测价值()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年03
页码:
244-248
栏目:
肿瘤介入
出版日期:
2021-03-29

文章信息/Info

Title:
The value of neutrophil-to-lymphocyte ratio in predicting the curative effect of TACE combined with apatinib for advanced hepatocellular carcinoma
作者:
王富权;  柴 斌;  周国锋
Author(s):
WANG Fuquan;  CHAI Bin;  ZHOU Guofeng.
Department of Radiology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Provincial Key Laboratory of Molecular Imaging, Wuhan, Hubei Province 430022, China
关键词:
【关键词】 阿帕替尼;  经肝动脉化疗栓塞;  中性粒细胞与淋巴细胞比值;  预测因子
文献标志码:
A
摘要:
【摘要】 目的 探究中性粒细胞与淋巴细胞比值（NLR）对TACE联合阿帕替尼治疗进展期肝癌疗效的预测价值。方法 回顾性分析2015年4月至2018年4月接受TACE联合阿帕替尼治疗的87例进展期肝细胞癌患者的临床资料。根据患者治疗前NLR，将患者分成NLR≥2.95组和NLR＜2.95组。通过比较两组患者的总生存时间（OS）、疾病进展时间（TTP）以及生存率来分析比较两组患者的疗效，并通过Cox回归模型分析影响患者OS的相关因素。结果 NLR＜2.95组患者的中位OS高于NLR≥2.95组患者（15个月比 11个月，P＜0.001），同时NLR＜2.95组中位TTP较NLR≥2.95组长（7个月比 4个月，P＜0.001）。对比两组生存率，NLR＜2.95组6、12及24个月生存率均高于NLR≥2.95组。通过多因素Cox回归分析，NLR≥2.95是影响患者OS的唯一独立危险因素（HR=2.67，95%CI：1.59～4.50，P＜0.001）。结论 进展期肝细胞癌患者接受TACE联合阿帕替尼治疗前NLR对疗效具有预测价值，治疗前NLR＜2.95患者较NLR≥2.95患者预后好。

参考文献/References:

［1］ Kang YK， Yau T， Park JW， et al. Randomized phase Ⅱ study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma［J］. Ann Oncol， 2015， 26： 2457-2463.
［2］ Fan W， Yuan G， Fan H， et al. Apatinib combined with transarterial chemoembolization in patients with hepatocellular carcinoma and portal vein tumor thrombus： a multicenter retrospective study［J］. Clin Ther， 2019， 41： 1463-1476.
［3］ 杨 庆，潘松松，施昌盛，等． 甲磺酸阿帕替尼联合TACE治疗中晚期肝癌的效果及对患者血清VEGF和MMP-9的影响［J］． 中华介入放射学电子杂志， 2019， 7：111-116．
［4］ Kan X， Liang B， Zhou G， et al. Transarterial chemoembolization combined with apatinib for advanced hepatocellular carcinoma：a propensity score matching analysis［J］. Front Oncol， 2020， 10： 970.
［5］ 翟 越，潘文秋，赵 卫，等． CalliSpheres联合阿帕替尼治疗肝癌的安全性和有效性［J］． 介入放射学杂志， 2020， 29：462-466．
［6］ Shaul ME， Fridlender ZG. Cancer- related circulating and tumor-associated neutrophils - subtypes， sources and function［J］. FEBS J， 2018， 285： 4316- 4342.
［7］ Andrejeva G， Rathmell JC. Similarities and distinctions of cancer and immune metabolism in inflammation and tumors［J］. Cell Metab， 2017， 26： 49-70.
［8］ Shoji F， Takeoka H， Kozuma Y， et al. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors［J］. Lung Cancer， 2019， 136： 45-51.
［9］ Lian L， Xia YY， Zhou C， et al. Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer［J］. Cancer Biomark， 2015， 15： 899-907.
［10］ Patel DA， Xi J， Luo J， et al. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer［J］. Breast Cancer Res Treat， 2019， 174： 443- 452.
［11］ Finn RS， Merle P， Granito A， et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC： additional analyses from the phase Ⅲ RESORCE trial［J］. J Hepatol， 2018， 69： 353-358.
［12］ Sergio A， Cristofori C， Cardin R， et al. Transcatheter arterial chemoembolization（TACE） in hepatocellular carcinoma（HCC）： the role of angiogenesis and invasiveness［J］. Am J Gastroenterol， 2008， 103： 914-921.
［13］ Balkwill F， Mantovani A. Inflammation and cancer： back to virchow?［J］. Lancet， 2001， 357： 539-545.
［14］ Mollinedo F. Neutrophil degranulation， plasticity， and cancer metastasis［J］. Trends Immunol， 2019， 40： 228-242.
［15］ Hoffmann TK， Dworacki G， Tsukihiro T， et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance［J］. Clin Cancer Res， 2002， 8： 2553-2562.
［16］ Sprinzl MF， Kirstein MM， Koch S， et al. Improved prediction of survival by a risk factor- integrating inflammatory score in sorafenib- treated hepatocellular carcinoma［J］. Liver Cancer， 2019， 8： 387- 402.
［17］ Chon YE， Park H， Hyun HK， et al.Development of a new nomogram including neutrophil-to- lymphocyte ratio to predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization［J］. Cancers（Basel）， 2019， 11： 509.
［18］ Tan W， Sun W， Li X， et al. Preablation neutrophil- to- lymphocyte ratio as an Independent prognostic factor in locally advanced hepatocellular carcinoma patients following radiofrequency ablation［J］. J Cancer Res Ther， 2018， 14： 84-89.
［19］ Chen L， Ke Z， Xiong F， et al. Platelet-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization plus apatinib in the treatment of advanced hepatocellular carcinoma［J］. Anticancer Drugs， 2020， 31： 966-972.

相似文献/References:

[1]范晓强,沈 杰,张雪娜,等.法舒地尔在肝癌血管介入治疗中的应用[J].介入放射学杂志,2011,(09):740.
　FAN Xiao-qiang,SHEN Jie,ZHANG Xue-na,et al.The application of Fasudil in treating vascular spasm occurred in interventional treatment for hepatocellular carcinomas[J].journal interventional radiology,2011,(03):740.
[2]徐森华,徐成兴,瞿春霞,等. 加味柴芍六君子汤联合经肝动脉化疗栓塞治疗原发性肝癌临床观察[J].介入放射学杂志,2014,(02):163.
　XU Sen? hua,XU Cheng? xing,QU Chun? xia,et al. Modified Chaishao Liujunzi decoction combined with TACE for the treatment of advanced primary liver cancer： a clinical observation[J].journal interventional radiology,2014,(03):163.
[3]房星宇,于 淼,杨倚天,等. 肝动脉化疗栓塞及射频消融治疗胰腺神经内分泌肿瘤肝转移的疗效和生存分析[J].介入放射学杂志,2013,(05):377.
　FANG Xing? yu,YU Miao,YANG Yi? tian,et al. Transarterial chemoembolization and radiofrequency ablation for liver metastases from pancreatic neuroendocrine tumors： an analysis of clinical effect and survival[J].journal interventional radiology,2013,(03):377.
[4]含 笑,吕维富. 经肝动脉化疗栓塞联合射频消融治疗原发性肝癌远期疗效的荟萃分析[J].介入放射学杂志,2013,(05):387.
　HAN Xiao,LV Wei? fu.. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma： a meta-analysis of long?蛳 term efficacy[J].journal interventional radiology,2013,(03):387.
[5]赵 松,陈学春,龙清云,等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,(11):908.
　ZHAO Song,CHEN Xue? chun,LONG Qing? yun,et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma： a systematic review and Meta analysis[J].journal interventional radiology,2013,(03):908.
[6]李亚华,段旭华,韩新巍,等.TACE术中应用三氧化二砷CalliSpheres载药栓塞微球治疗BCLC B期原发性肝癌13例 [J].介入放射学杂志,2019,28(03):232.
　LI Yahua,DUAN Xuhua,HAN Xinwei,et al.TACE by using arsenic trioxide drug- bearing CalliSpheres beads for the treatment of BCLC stage B HCC： preliminary results in 13 patients[J].journal interventional radiology,2019,28(03):232.
[7]陈成,沈艳峰,董云,等.阿帕替尼联合TACE治疗原发性肝癌有效性和安全性meta分析 [J].介入放射学杂志,2020,29(03):251.
　CHEN Cheng,SHEN Yanfeng,DONG Yun,et al.Apatinib combined with TACE for primary liver cancer: a meta-analysis of its effectiveness and safety[J].journal interventional radiology,2020,29(03):251.
[8]张 磊,侯忠衡,王 祁,等.经肝动脉化疗栓塞治疗中期肝癌预后的预测模型的建立和验证 [J].介入放射学杂志,2021,30(12):1236.
　ZHANG Lei,HOU Zhongheng,WANG Qi,et al.The establishment and validation of nomogram model used for predicting the prognosis of patients with mid-stage HCC after receiving TACE[J].journal interventional radiology,2021,30(03):1236.

备注/Memo

备注/Memo:
（收稿日期：2020- 09- 08）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2021-03-24